Rituxan (rituximab) - Roche
Brukinsa (zanubrutinib) - BeOne Medicines
LATE SEROCONVERSION AND BTKI-INDUCED FLARE IN CRYOGLOBULINEMIC WALDENSTRÖM MACROGLOBULINEMIA: A CASE REPORT (SIE 2026) - Oct 6, 2026 - Abstract #SP092; "The pheno- menon of late seroconversion and the BTKi-induced flare of stable ulcers in a TP53-negative patient underscore the com- plexity of managing cryoglobulinemic WM. The transition to Zanubrutinib and the planned integration of Rituximab rep- resent a necessary paradigm shift to overcome the "flare paradox" and ensure definitive tissue healing." 
Case report • Clinical • Complement-mediated Rare Disorders • Hematological Disorders • Lymphoma • Lymphoplasmacytic Lymphoma • Waldenstrom Macroglobulinemia • MYD88 • TP53
https://manage.ercongressi.it/storage/ercongressi/article/pdf/291/14496-SIE2026%20-%20abstract%20book.pdf
 
M. Draisci; S. Franceschetti; R. Marcolin; S. Marinoni; A. Corso
 
Oct 6, 2026
 
Prev Next